Castleman Disease
📧 Sign up to get email alerts when something new happens for Castleman Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-03-24EMA Authorised: Sylvant (siltuximab) — Recordati Netherlands B.V.
The European Medicines Agency has authorized Sylvant (siltuximab) for giant lymph node hyperplasia (Castleman disease) with accelerated asse…
-
EMA approval · 2014-03-21European Medicines Agency recommends authorisation of first medicine for Castleman's disease
The EMA recommends authorisation of the first medicine specifically for Castleman’s disease, marking a pivotal step in treatment options for…